The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro

The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro

Abstract Background The pathogenesis of spondyloarthritis (SpA) involves both inflammation and new bone formation in the spine. In line with this, the disease has been characterized as both inflammatory and fibrotic. The current treatment dampens inflammation while new bone formation can progress. T...

Full description

Bibliographic Details
Main Authors: Julie Stougaard, Søren Lomholt, Pernille Ommen, Jens Kelsen, Tue W. Kragstrup
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Rheumatology
Subjects:
Spondyloarthritis
Inflammation
Fibroblast
Myofibroblast
Osteoblast
Pirfenidone
Online Access:http://link.springer.com/article/10.1186/s41927-018-0040-9

Internet

http://link.springer.com/article/10.1186/s41927-018-0040-9

Similar Items